Exicure is a clinical stage biotechnology company developing a new class of immunomodulatory and gene silencing drugs against validated targets. Its 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Its lead programs address diseases from inflammatory disorders to oncology.
State of Ownership
CEO & Co-Founder, Zapnito
Chief Product Officer, Zapnito
Sales Account Executive, Springer Nature